Exercise in Prostate Cancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
About this trial
The goal of this clinical trial is to learn how exercise intervention affects circulating tumor cells (CTC) in men with advanced prostate cancer. The primary objective is to determine if an exercise intervention decreases CTCs in men with advanced prostate cancer. Participants will have baseline screening assessments, followed by 12 weeks of exercise intervention, and then follow-up assessments 12 weeks after the end of the exercise intervention.
Eligibility criteria
Qualifiers
Men with metastatic prostate adenocarcinoma
Currently taking androgen deprivation therapy alone or with an oral androgen axis inhibitor (abiraterone, enzalutamide, darolutamide, or apalutamide are permitted) and have been on treatment for at least 3 months
Elevated (PSA > 1ng/mL) or rising PSA (any numerical increase based on at least 2 PSA readings at least 2 weeks apart)
Any number of prior therapies (prior chemo, radium-223, etc.) is allowed
Disqualifiers
Small cell carcinoma of the prostate
Unable to participate or monitor exercise compliance due to conditions such as impaired cognition
Moderate to severe bone pain that limits any activities of daily living, including use of narcotics for prostate cancer related pain
Clinical progression requiring a change in systemic therapy or the addition of palliative radiation for symptom control
Trial design
Treatments tested in this trial
- Exercise Intervention
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lead sponsor
Physical Medicine & Rehabilitation Educ Research Foundation, Inc
Collaborator
Source ClinicalTrials.gov